

Name of the Issue: Supriya Lifescience Limited

1 Type of Issue Initial Public Offer

2 Issue Size (Rs. Mn) 7000.00*

*Source: Prospectus dated December 21, 2021

3 Grade of issue along with name of the rating agency

Name NA
Grade NA

4 Subscription Level (Number of times) 73.9412*

* excluding Anchor Investor Portion and after removing multiple and duplicate bids

Source: Minutes for basis of allotment dated December 23, 2021

5 QIB Holding (as a %age of Outstanding Capital) as disclosed to the stock exchanges

Particulars	%age
(i) On Allotment **	23.81%
(ii) at the end of the 1st Quarter immediately after the listing of the issue (December 31, 2021)	18.21%
(iii) at the end of 1st FY (March 31, 2022)	14.86%
(iv) at the end of 2nd FY (March 31, 2023)	5.65%
(v) at the end of 3rd FY (March 31, 2024) *	17.69%

**Basis of Allotment (excluding pre-issue QIB holding)

* QIB Holding not disclosed as reporting for relevant period has not been completed.

6 Financials of the issuer

Parameters	(Rs. Million)		
	1st FY (March 31,2022)	2nd FY (March 31,2023)	3rd FY (March 31,2024)*
Income from operations	537.62	4,609.38	5,703.70
Net Profit/(Loss) for the period	151.81	898.57	1,191
Paid-up equity share capital	160.97	160.97	161
Reserves excluding revaluation reserves	5,995.91	6,833.62	7,993

7 Trading Status

The equity shares of Supriya Lifescience Limited are listed on both the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE") (and together with BSE the "Stock Exchanges")

The equity shares have not been suspended or delisted.

Particulars	Status
(i) at the end of 1st FY (March 31, 2022)	Frequently traded on BSE and NSE
(ii) at the end of 2nd FY (March 31, 2023)	Frequently traded on BSE and NSE
(iii) at the end of 3rd FY (March 31, 2024)	Frequently traded on BSE and NSE

8 Change in Directors of Issuer from the disclosures in the offer document

Particulars	Name of Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2022)	Not Applicable	
(ii) at the end of 2nd FY (March 31, 2023)	Not Applicable	
(iii) at the end of 3rd FY (March 31, 2024)	Mr. Manoj Dorlikar	Resignation
	Mr. Balasaheb Sawant	Appointment
	Ms. Shivani Wagh	Re- appointment

* Changes in Directors of Issuer not updated as the relevant financial years have not been completed

9 Status of implementation of project/ commencement of commercial production

(i) as disclosed in the offer document	Not applicable
(ii) Actual implementation	Not applicable
(iii) Reasons for delay in implementation, if any	Not applicable

10 Status of utilization of issue proceeds

(i) As disclosed in the offer document

(Rs. Million)

Particulars	Amount which will be financed from Net Proceeds	Estimated Utilisation of Net Proceeds in Fiscal 2022	Estimated Utilisation of Net Proceeds in Fiscal 2023	Estimated Utilisation of Net Proceeds in Fiscal 2024
Funding capital expenditure requirements of the Company	923.00	436.13	436.13	50.74
Repayment and/or pre-payment, in full or part, of certain borrowings availed by the Company	600.00	600.00	-	-
General corporate purposes	359.52	150.00	209.52	-
Total	3,068.65	1,186.13	645.65	50.74

(ii) Actual utilization

(Rs. Million)

Particulars	Amount which will be financed from Net Proceeds	During the Quarter	At the end of the quarter	Total unutilised amount
Funding capital expenditure requirements of the Company	923.00	215.65	923.00	-
Repayment and/or pre-payment, in full or part, of certain borrowings availed by the Company	600.00	-	600.00	-
General corporate purposes (Incl. Offer Expenses)*	379.99	19.04	379.99	-
Total	1,902.99	234.69	1,902.99	-

Source: Stock Exchange Filings * On finalization of offer expenses, the amount proposed to be utilized for General Corporate Purposes is revised to INR. 379.99

(iii) Reasons for deviation, if any

Objects Name	Completion Date		Delay (No. of days / months)	Comments of the Board	
	As per Offer Document	Actual		Reason of delay	Proposed Course of Action
Capex	FY 21-22	FY 22-23	Approx. 12 Months	Due to Change in scope of work ,designing of equipment got changes which leads to delay in implementation	In FY 22-23 the same will be implemented.

(iii) Reasons for deviation, if any

11 Comments of monitoring agency, if applicable

(i) Comments on use of funds	Not applicable
(ii) Comments on deviations, if any, in the use of proceeds of the Issue from the objects stated in the Offer document	Not applicable
(iii) Any other reservations expressed by the monitoring agency about the end use of funds	Not applicable

12 Pricing Data

Designated Stock Exchange	BSE
Issue Price (Rs.)	274.00
Listing Date	28-Dec-21

Price parameters	At close of listing day - December 28, 2021	Close of 30th calendar day from listing day	Close of 90th calendar day from listing day - March 27, 2022	As at the end of the 1st FY after the listing of the issue (31st March,2022)		
				Closing price	High	Low
Market Price	390.35	489.40	470.35	492.9	601.9	376.8
Sensex*	57,897.48	57,858.15	57,593.49	58,568.50	61,765.60	47,705.80
Price parameters	As at the end of the 2nd FY after the listing of the issue (31st March,2023)			As at the end of the 3rd FY after the listing of the issue (31st March,2024)		
	Closing price	High	Low	Closing price	High	Low
Market Price	190.70	515.35	170.05	331.75	393.70	367.55
Sensex*	58,991.5	63,583.07	50,921.2	73,651.4	74,245.2	58,793.1

* Being index of BSE, the designated stock exchange

(1) The pricing data is not disclosed as the relevant fiscal years have not been completed

13 Basis for Issue Price

Accounting ratio	Face Value per share (Rs.)	As disclosed in offer document*	At the end of 1st FY (March 31,2022)***	At the end of 1st FY (March 31,2023)	At the end of 1st FY (March 31,2024)**
Company					
EPS (Basic)		2	16.92	18.86	14.80
Peer Group:					
		10	69.00	-16.18	-6.16
		10	62.85	49.74	127.14
		10	30.09	22.12	17.97
		10	(5.04)	25.29	-3.18
		2	74.75	111.52	68.11
			46.33	38.50	40.78
					32.88

	Company					
P/E	<i>Consolidated</i>	2	-	26.13	17.09	22.42
	Peer Group:					
	<i>Solara Active Pharma Sciences Ltd</i>	10	18.4	-41.11	-53.31	-2.36
	<i>Neuland Laboratories Ltd</i>	10	27.8	20.64	14.15	26.86
	<i>Aarti Drugs Ltd</i>	10	16.8	19.39	18.80	23.38
	<i>Wanbury Ltd</i>	10	(13.2)	3.36	-11.74	15.70
	<i>Divis Laboratories Ltd</i>	2	65.3	39.49	41.49	57.02
	Industry Avg		23.0	8.4	1.9	24.1
RoNW	Company					
	<i>Consolidated</i>	2	46.04%	100.86%	1.80%	14.61%
	Peer Group:					
	<i>Solara Active Pharma Sciences Ltd</i>	10	13.90%	-3.82%	-1.48%	-60.71%
	<i>Neuland Laboratories Ltd</i>	10	10.25%	7.59%	16.50%	23.39%
	<i>Aarti Drugs Ltd</i>	10	30.70%	19.78%	13.83%	11.07%
	<i>Wanbury Ltd</i>	10	8.07%	-347.87%	143.11%	108.80%
<i>Divis Laboratories Ltd</i>	2	21.35%	25.24%	14.23%	11.79%	
	Industry Avg		16.85%	-59.81%	37.24%	18.87%
NAV per share	Company					
	<i>Consolidated</i>	2	36.75	10.69	0.23	0.02
	Peer Group:					
	<i>Solara Active Pharma Sciences Ltd</i>	10	443.3	2.36%	2.40%	3.85%
	<i>Neuland Laboratories Ltd</i>	10	613.0	1.53%	1.31%	1.01%
	<i>Aarti Drugs Ltd</i>	10	98.0	8.94%	7.77%	7.17%
	<i>Wanbury Ltd</i>	10	(62.5)	-139.45%	-450.4%	117.2%
<i>Divis Laboratories Ltd</i>	2	350.1	0.45%	0.42%	0.39%	
	Industry Avg		288.4	-25%	-88%	26%

Notes

* Sourced from Prospectus dated December 21, 2021.

*** Annual Reports of the respective Company for the respective year

P/E based on basic EPS for the fiscal year / price on BSE for March 31, 2022 and March 31, 2023

14 Any other material information

Particulars	Date
Dr. Shireesh Ambhaikar has agreed to extend his services on a retainership basis for a period of 2 years effective October 1, 2022 where he will be designated as Technical Head for certain projects of Supriya Lifescience Limited	September 27, 2022
The Board has in its meeting held today i.e. September 27, 2022 approved the appointment of Mr. Rajeev Kumar Jain as Chief Executive Officer and Key Managerial Personnel of the Company, who will be joining on October 3, 2022	September 27, 2022

Source: Stock Exchange websites i.e. www.bseindia.com and www.nseindia.com